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ABSTRACT
Immunotherapy has transformed lung cancer care in
recent years. In addition to providing durable responses
and prolonged survival outcomes for a subset of patients
with heavily pretreated non-small cell lung cancer
(NSCLC), immune checkpoint inhibitors (ICIs)— either
as monotherapy or in combination with other ICIs or
chemotherapy—have demonstrated benefits in first-
line therapy for advanced disease, the neoadjuvant
and adjuvant settings, as well as in additional thoracic
malignancies such as small-cell lung cancer (SCLC) and
mesothelioma. Challenging questions remain, however, on
topics including therapy selection, appropriate biomarker-
based identification of patients who may derive benefit,
the use of immunotherapy in special populations such
as people with autoimmune disorders, and toxicity
management. Patient and caregiver education and support
for quality of life (QOL) is also important to attain maximal
benefit with immunotherapy. To provide guidance to
the oncology community on these and other important
concerns, the Society for Immunotherapy of Cancer (SITC)
convened a multidisciplinary panel of experts to develop
a clinical practice guideline (CPG). This CPG represents
an update to SITC’s 2018 publication on immunotherapy
for the treatment of NSCLC, and is expanded to include
recommendations on SCLC and mesothelioma. The
Expert Panel drew on the published literature as well as
their clinical experience to develop recommendations
for healthcare professionals on these important aspects
of immunotherapeutic treatment for lung cancer and
mesothelioma, including diagnostic testing, treatment
planning, immune-related adverse events, and patient
QOL considerations. The evidence- and consensus-
based recommendations in this CPG are intended to give
guidance to cancer care providers using immunotherapy to
treat patients with lung cancer or mesothelioma.
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INTRODUCTION
Lung cancer is the leading cause of cancer-
related death globally1 and despite significant

declines in the overall mortality rate, the
disease is still expected to account for 21% of
all cancer deaths in the US in 2022.2 The advent
of immunotherapies, specifically immune
checkpoint inhibitors (ICIs), has contributed
to improved outcomes in lung cancer. Since
the initial US Food and Drug Administration
(FDA) approval of nivolumab for metastatic
non-
small cell lung cancer (NSCLC) after
prior treatment with chemotherapy in 2015,3
additional ICIs have become standard of care
(SOC) options in earlier lines of therapy, as
components of combination regimens, and
in unresectable stage III NSCLC, as well as in
the adjuvant and neoadjuvant settings. The
FDA-approved ICIs for lung cancer and mesothelioma at the time of guideline publication
are pembrolizumab, nivolumab, ipilimumab,
atezolizumab, cemiplimab, and durvalumab,
with specific indications for each.4–12 Additionally, ICIs have now been approved by
the FDA for the treatment of other thoracic
malignancies including small-cell lung cancer
(SCLC),13 and pleural mesothelioma.14
Immunotherapy has profoundly expanded
and evolved the treatment landscape for lung
cancers in recent years, and oncologists need
practical guidance in the appropriate use of
the available agents.
ICIs are monoclonal antibodies (mAbs)
that target endogenous autoregulatory pathways to unleash antitumor immune responses.
Even though many cancer cells present
neoantigens that are recognized by cytotoxic
T cells,15 tumors avoid eradication by the
immune system through multiple mechanisms, including T cell exclusion and suppression of effector functions.16 Contributing to
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the immunosuppressive milieu are checkpoint proteins
on tumor and/or immune cells, which inhibit T cell
activation, proliferation, and receptor signaling through
a variety of mechanisms.17 18 At the time of manuscript
publication, the majority of FDA-approved ICIs target the
programmed cell death protein 1 (PD-1)/programmed
death-
ligand 1 (PD-
L1) axis (ie, PD-
(L)1), which is a
receptor-ligand pair involved in tumor immune suppression that plays a role in the maintenance of peripheral
tolerance in healthy tissues by inhibiting downstream
signaling through CD28 upon T cell receptor activation.19 20 Anti-PD-(L)1 ICIs may have activity as monotherapies, but combinations with chemotherapies or
anti-angiogenics may be necessary for maximal benefit for
some tumors.6 9 21 22 Additionally, the nivolumab plus ipilimumab dual-ICI regimen has been approved for NSCLC
and pleural mesothelioma.3 23 Dual ICI with 2 cycles of
chemotherapy has also been approved for NSCLC.24
Nivolumab is an anti-
PD-
1 mAb and ipilimumab is a
mAb against cytotoxic T lymphocyte antigen-4 (CTLA-4),
which also functions by limiting CD28 co-stimulation at
the T cell receptor.17 18 25 The identification of additional
immune checkpoints beyond PD-(L)1 and CTLA-4 is an
ongoing area of investigation, as is the optimal chemotherapy or targeted therapy backbone for ICI combination therapies in specific disease settings.
Although some patients with lung cancer achieve deep
and durable responses with ICIs, not all patients benefit
and many tumors are resistant to treatment, either
at baseline or through acquired mechanisms.26 27 To
support the oncology community and provide evidenceand consensus-
based recommendations on immunotherapy for lung cancer and mesothelioma, the Society
for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a new clinical
practice guideline (CPG) for NSCLC, SCLC and mesothelioma, covering immunotherapy-specific topics such
as recommended immunotherapies, diagnostics and
biomarkers, monitoring response to treatment, special
patient populations, toxicity management, and quality of
life (QOL) considerations. The recommendations within
this guideline are not intended to supplant sound clinical
judgment, but rather to provide clinicians with the most
up-to-date expert recommendations regarding the integration of immunotherapy into the treatment of patients
with lung cancer or mesothelioma.

GUIDELINE DEVELOPMENT METHODS
The Institute of Medicine’s (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines28 were
used as a model to develop the recommendations in this
manuscript. IOM standards dictate that guideline development is led by a multidisciplinary expert panel using
a transparent process where both funding sources and
conflicts of interest are readily reported. This clinical
practice guideline is intended to provide guidance and
2

is not a substitute for the professional judgment of individual treating physicians.
Conflict of interest management
As outlined by IOM standards, all financial relationships
of expert panel members that might result in actual,
potential, or perceived conflicts of interest were individually reported. Disclosures were made prior to the onset
of manuscript development and updated on an annual
basis. In addition, panel members were asked to articulate any actual or potential conflicts at all key decision
points during guideline development, so that participants
would understand all possible influences, biases, and/
or the diversity of perspectives on the panel. Although
some degree of relationships with outside interests are
to be expected among experts, panel candidates with
significant financial connections that may compromise
their ability to fairly weigh evidence (either actual or
perceived) were not eligible to participate in guideline
development.
Recognizing that guideline panel members are among
the leading experts on the subject matter under consideration and guideline recommendations should have
the benefit of their expertise, any identified potential
conflicts of interests were managed as outlined in SITC’s
disclosure and conflict of interest resolution policies.
As noted in these policies, panel members disclosing a
real or perceived potential conflict of interest may be
permitted to participate in consideration and decision-
making of a matter related to that conflict, but only if
deemed appropriate after discussion and agreement by
the expert panel.
The financial support for the development of this
guideline was provided solely by SITC. No commercial
funding was received.
Recommendation development
Panel recommendations are based on literature evidence,
where possible, and clinical experience, where appropriate. Consensus for the recommendations herein was
generated by open communication and scientific debate
in small-group and whole-group settings, surveying and
responses to clinical questionnaires, as well as formal
voting in consensus meetings.
For transparency, a draft of this CPG was made publicly
available for comment during the development process
and prior to publication. All comments were evaluated
and considered for inclusion into the final manuscript
according to the IOM standard.
Evidence rating
The evidence- and consensus-
based recommendations
of the panel were refined throughout the development
process in order to obtain the highest possible agreement
among the experts, however, the minimum threshold was
defined as 75% approval among the voting members.
Evidence supporting panel recommendations was graded
according to the Oxford Centre for Evidence-
Based
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Table 1 Summary of ‘The Oxford Levels of Evidence 2’ (adapted from Oxford Centre for Evidence-Based Medicine Levels of
Evidence Working Group)
Level 1

Level 2

Level 3

Level 4

Level 5

Systematic review or
meta-analysis

Randomized trial or
observational study
with dramatic effect

Non-randomized,
controlled cohort, or
follow-up study

Case series, case–
control, or historically
controlled study

Mechanism-based
reasoning

Medicine (OCEBM) Levels of Evidence Working Group
‘The Oxford Levels of Evidence 2’ (2016 version). A
summary of the OCEBM grading scale may be found in
table 1. The level of evidence (LE) for a given consensus
recommendation is expressed in parentheses following
the recommendation (eg, LE:1). Recommendations
without an associated LE were based on expert consensus.
DIAGNOSTIC TESTS AND BIOMARKERS
Biomarker testing may identify patients who are more
likely to derive benefit from regimens incorporating
targeted therapies or immunotherapies as opposed to
cytotoxic chemotherapy alone, and thus has become an
essential component in determining the optimal treatment of patients with NSCLC. Although biomarkers
for patient selection for other thoracic malignancies
are an ongoing area of research, PD-L1 expression in
SCLC or mesothelioma is not known to be predictive of
benefit withimmunotherapy at this time. While ICIs have
improved clinical outcomes for some patients, only a
subset of patients experience deep, durable responses as
a result of ICI therapy.29
For immunotherapy specifically, research is ongoing to
identify biomarkers with predictive value for response to
ICIs for patients with lung cancer. Across solid tumors,
three tumor biomarkers have been validated thus far to
predict improved outcomes after ICI treatment: PD-L1
expression, microsatellite instability (MSI), and tumor
mutational burden (TMB). FDA-
approved indications
for some ICIs, including in lung cancer, are dependent on PD-L1 expression above a specific cut-off by an
approved companion diagnostic (discussed in the PD-L1
expression section below); additionally, pembrolizumab
is approved for tissue-
agnostic use in tumors that are
MSI-high (MSI-H) and/or deficient in mismatch repair
(dMMR) as well as in tumors with high TMB (TMB-H).30
PD-L1 expression
At the time of manuscript writing, all FDA-approved ICI
regimens for lung cancer and mesothelioma include one
agent that targets the PD-(L)1 axis. As such, several clinical trials have attempted to stratify patients by the level of
PD-L1 expression in tumor cells (TCs) and/or infiltrating
immune cells (ICs) in an effort to identify patients most
likely to benefit from ICI therapy. Currently, eligibility for
four of the ICIs indicated for the treatment of advanced
NSCLC is conditional based on PD-L1 expression above
a specific cut-off (currently, no FDA approvals for SCLC
or mesothelioma are dependent on PD-L1 expression).

Additionally, eligibility for ICI therapy in the adjuvant
setting requires confirmed tumor PD-L1 expression by
an FDA-approved test (data supporting the approval, as
well as outcomes across PD-
L1 expression subgroups,
are described in the Resectable stage II to IIIA NSCLC
section). For all of the agents with indications for PD-L1-
positive NSCLC, the FDA has approved corresponding
companion diagnostics that assess PD-L1 expression using
immunohistochemistry (IHC). It is important to note
that these assays are not all equivalent or interchangeable, as will be discussed below in the Concordance in
PD-L1 testing section. Additionally, different thresholds
for PD-L1 expression define eligibility across indications.
The most commonly used cut-off values are PD-L1 expression ≤1%, 1%–49%, and ≥50%. In real-world analyses,
roughly 44% of tumors have PD-L1 expression <1%, 25%
of tumors have PD-L1 expression 1%–49%, and around
31% of tumors have PD-L1 expression ≥50%.31 A comprehensive review of PD-L1 as a predictive biomarker was
published in 2021.32
The VENTANA PD-L1 SP142 assay is the FDA-approved
companion diagnostic for atezolizumab, an anti-PD-L1
ICI, which may be used in the treatment of PD-L1-high
NSCLC as a first-line monotherapy in patients with no
EGFR/ALK alterations.33 The SP142 assay defines high
PD-L1 expression in lung cancer as ≥50% of TCs staining
positive for PD-L1 (TC ≥50%), or as PD-L1-expressing
ICs covering ≥10% of the tumor (IC ≥10%).33 The FDA
approval of atezolizumab for this indication was based
on data from IMpower110 (NCT02409342), in which the
subgroup of patients with high PD-L1 expression exhibited a significant overall survival (OS) advantage with ICI
treatment compared with platinum-based chemotherapy,
a benefit that was not seen for patients with tumors in
other PD-L1 expression categories (TC ≥5% or IC ≥5%;
TC ≥1% or IC ≥1%).34
The anti-PD-1 ICI nivolumab is approved in combination with ipilimumab for the first-line treatment of metastatic NSCLC, if no EGFR/ALK alterations are present
and tumors are PD-L1 ≥1% (≥1% of TCs in the sample
staining positive for PD-
L1).3 23 The PD-
L1 IHC 28–8
pharmDx assay was used to evaluate PD-L1 expression
during the CheckMate 227 trial (NCT02477826), and
patients with PD-
L1 ≥1% treated with nivolumab and
ipilimumab exhibited a significant OS advantage over
patients treated with platinum-doublet chemotherapy.35
The 28–8 assay is FDA-approved for this indication as a
companion diagnostic.
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Pembrolizumab, an ICI that targets PD-
1, has two
NSCLC indications that require PD-L1 testing. For both
indications, PD-L1 expression is measured by the PD-L1
IHC 22C3 pharmDx companion diagnostic, which
measures PD-L1 expression on TCs only.30 In both cases,
the threshold for PD-L1 positivity is tumor proportion
score (TPS) ≥1%. Pembrolizumab may be used as a first-
line monotherapy for PD-
L1-
positive tumors without
EGFR/ALK alterations, if the disease is either metastatic
or stage III and the patient is not a candidate for surgery
or radiotherapy. Pembrolizumab is also indicated for the
treatment of PD-
L1-
positive relapsed/refractory (R/R)
NSCLC, if patients have previously received platinum-
based chemotherapy and targeted therapies for EGFR/ALK
alterations (if appropriate). During the KEYNOTE-042
trial (NCT02220894) evaluating pembrolizumab as a
first-
line monotherapy, statistically significant improvements in OS over chemotherapy were observed for the
TPS ≥1%, TPS ≥20%, and TPS ≥50% subgroups.8 Similarly, both the TPS ≥1% and TPS ≥50% subgroups exhibited significant improvements in OS and overall response
rate (ORR) in comparison to docetaxel in KEYNOTE-010
(NCT01905657), a trial evaluating pembrolizumab in the
R/R NSCLC setting.7 Progression-free survival (PFS) was
also improved in the TPS ≥50% subgroup with pembrolizumab compared with docetaxel. Of note, the 28–8 assay
has been found to be equivalent to the 22C3 assay,36 and
these assays are used interchangeably for both nivolumab
and pembrolizumab.
Cemiplimab, an anti-PD-1 mAb, has also been approved
for the treatment of NSCLC tumors that are PD-
L1-
positive. Both pembrolizumab and cemiplimab are indicated for the treatment of tumors that are PD-L1-positive
by the 22C3 assay. However, the threshold for PD-
L1
positivity for cemiplimab is TPS ≥50%. Cemiplimab
monotherapy may be used for the first-line treatment
of locally advanced (and not eligible for surgical resection or definitive chemoradiation) or metastatic NSCLC
that is PD-L1-positive and has no EGFR, ALK, or ROS1
genetic alterations.37 Approval was based on the phase
III EMPOWER-
Lung 1 trial (NCT03088540), which
compared SOC chemotherapy to cemiplimab monotherapy and showed significant OS and PFS benefit in the
PD-L1-positive (TPS ≥50%) population.11
Concordance in PD-L1 assays and considerations for testing
The existence of multiple assays that measure PD-
L1
expression, each developed for use with a different ICI
and developed using different protocols, scoring algorithms, and antibodies has raised questions of generalizability of positive results across IHC staining platforms.
Harmonization efforts are ongoing, however, the predictive value of individual PD-L1 assays for indications other
than reported in the registrational clinical trials leading
to each FDA approval is unknown. The Blueprint Phase
1 study included 471 tumor samples and compared the
SP142, 28–8, 22C3, and the VENTANA PD-
L1 SP263
(used for patient selection with durvalumab, but not in
4

lung cancer diagnostics) assays. Through both manual
and automated image analysis methods measuring the
number of PD-
L1 staining TCs (excluding ICs), the
28–8, 22C3, and the SP263 assays showed high levels of
concordance, while the SP142 assay did not correlate as
strongly with any of the other assays.36 However, this study
did not assess the concordance of IC staining. Results
from Blueprint Phase 2 (in which ICs were included in
the analysis) confirmed interchangeability of the 22C3,
28–8, and SP263 assays.38 The SP142 assay has also been
shown to stain fewer TCs compared with the other
assays.39 40 A similar study that compared IHC using the
22C3, SP263, SP142, and E1L3N antibody clones to test
97 NSCLC samples found that E1L3N can be used interchangeably with the 22C3 and SP263 antibodies.41 The
results of assay concordance studies to date, however,
have not been based on head-to-head comparisons. Also
of note, the E1L3N antibody has not received approval as
a companion or complementary diagnostic—although in
many cases institutions use it or other reagents as components of in-house assays, also known as laboratory developed tests. Many laboratories do not offer multiple tests
for PD-L1, but rather choose to validate only one or two
of the four or five options. Notably, no major prospective
studies have examined cross-assay correlations between
PD-L1 expression and measurements of clinical outcome
(eg, OS and PFS).32
Tissue-agnostic indications for ICIs
At the time of manuscript preparation, pembrolizumab
is approved for two tissue-agnostic indications for tumors
with high levels of genomic instability, namely MSI-H/
dMMR and TMB-H. To identify tumors that are MSI-H/
dMMR, no specific companion diagnostic was mandated
in the original FDA approval,30 which was based on a
pooled analysis of 149 patients with MSI-H solid tumors
across five clinical trials (KEYNOTE-016, KEYNOTE-164,
KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158). In
February 2022, the FoundationOne CDx was approved
as a companion diagnostic to identify patients with
MSI-H solid tumors who may be appropriate for treatment with pembrolizumab. It is important to note that it
is uncommon for lung cancers to be MSI-H. In an analysis of 10,701 tumor-normal sample pairs from 39 cancer
types, lung adenocarcinomas were MSI-
H at a rate of
0.53%, and lung squamous cell carcinomas were MSI-H
at a rate of 0.60%.42
The FDA also approved pembrolizumab for the treatment of patients with solid tumors that are TMB-
H
(defined as ≥10 mutations/megabase by the FDA-
approved FoundationOne CDx companion diagnostic).
Approval was based on KEYNOTE-158, which included
a total of 1,032 patients (none with NSCLC).43 Notably,
data are lacking for the predictive and prognostic
value of TMB-H in the context of lung cancers treated
with immunotherapy. During the CheckMate 227 trial,
which evaluated nivolumab in combination with ipilimumab in advanced NSCLC and stratified patients by
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biomarker status, survival endpoints were met regardless
of TMB status.44 The optimal cut-off threshold for TMB-H
remains an ongoing area of investigation and variability
across panel assays remains an obstacle. A recent effort
pioneered by Friends of Cancer Research demonstrated
that panel sizes of >667 Kbb are necessary for optimal
concordance with whole-
exome sequencing-
based
methods of assessing TMB, however, statistical methods
can assist in filtering out pathogenic and germline variants for more consistent results.45
Tissue acquisition considerations for immunotherapy
For biomarkers that rely on IHC staining (ie, PD-
L1
testing), it is important to consider the conditions under
which tissue samples are stored and tested. Acquisition
of sufficient tissue for multiple assays is also paramount.
There is evidence that, while archived specimens can be
used to successfully measure PD-L1 expression, PD-L1
immunoreactivity is gradually lost over time while the
specimen is in storage. One analysis of formalin-fixed
paraffin-
embedded tissue samples from 1,546 patients
with NSCLC found that concordance between recently-
acquired (<3 months old) and archived samples was
highest with archived samples less than 3 years old.46
Regardless of the age of the sample, however, there is
no evidence that results significantly differ between
PD-L1 assays performed in in-house Clinical Laboratory
Improvement Amendments (CLIA)-
certified laboratories compared with those returned from samples sent to
centralized testing laboratories.
Molecular testing
Targeted therapies exist to inhibit the aberrant protein
signaling resulting from common NSCLC genetic variants, including mutations or genetic alterations in EGFR,
ALK and ROS1. Therefore, for some patients, molecular
testing can guide eligibility for treatment with appropriate targeted therapies. Comprehensive recommendations on genetic testing are beyond the scope of this
immunotherapy-focused CPG, but several international
organizations have published statements recommending,
at minimum, routine testing for EGFR, ALK, ROS1,
BRAF, MET exon 14, RET, NTRK, and KRAS G12C alterations.47–50 It is likely that the list of genes selected for
molecular testing in lung cancer will continue to increase
as new targeted agents are approved by the FDA.
Panel recommendations
Comprehensive next-
generation sequencing (NGS)
testing of tumor tissue is recommended for all
patients with metastatic non-squamous NSCLC and
select patients with squamous carcinoma of the lung
(eg, never-smokers) if feasible (LE: 2).
► When NGS is not possible, tumor tissue should be
tested for EGFR, ALK, ROS1, BRAF, MET ex14, RET,
NTRK, and KRAS G12C alterations for all patients
with non-squamous NSCLC and selected patients with
squamous cell.
►

►

►

►

►

►

►

►

►

►

Tumor tissue should be tested for molecular driver
oncogenes for patients with metastatic NSCLC
adenocarcinoma with any smoking history, and for
patients with light or never smoking history with non-
adenocarcinoma histology (LE: 3).
ICIs should not be initiated until the results of molecular driver mutation testing are available, regardless
of tumor PD-L1 expression status.
Testing for tumor PD-
L1 expression should be
performed for patients with metastatic (stage IV)
NSCLC of any histology to predict the likelihood of
clinical benefit from anti-PD-(L)1 ICI therapy (LE: 2).
Testing for tumor PD-L1 expression can be considered, but is not required, for patients with stage III
unresectable NSCLC to predict the likelihood of clinical benefit from anti-PD(L)1 ICI therapy.
For resectable stage II to IIIA NSCLC, testing for
tumor PD-
L1 expression should be performed to
be considered for atezolizumab therapy in the adjuvant setting following resection and platinum-based
chemotherapy (LE:2).
For PD-
L1 assessment, the 22C3, 28–8, and SP263
assays are interchangeable. The SP142 assay is not
interchangeable and does not perform equivalently
to the other assays listed (LE: 3).
Archived or fresh biopsy material can be used for
PD-L1 assessment (LE: 3). Previously cut slides that
are less than 3 months old can be used for PD-L1
assessment.
Testing for PD-L1 expression in SCLC or mesothelioma is not known to be predictive of benefit with
immunotherapy at this time.
TMB and MSI are the basis for tumor-agnostic indications for ICI therapy and have demonstrated clinical
utility in many tumor types, but in lung cancer there
are insufficient data to recommend routine testing for
these biomarkers (LE: 2).

NON-SMALL CELL LUNG CANCER
The SOC for the treatment of NSCLC includes surgery,
radiation, and systemic therapies. As discussed earlier,
targeted therapies, especially those that specifically
disrupt tumors with alterations in specific genes, such
as EGFR, ALK, and ROS151–53 have been approved for
the treatment of patients with advanced NSCLC and
the respective genetic variants. The role for immunotherapy is limited in oncogene-driven NSCLC at the time
of manuscript writing. ICI monotherapy has provided
limited clinical benefit to patients with molecular driver
gene mutated NSCLC—one retrospective analysis that
included 551 patients with mutations in KRAS, BRAF,
ROS1, MET, EGFR, HER2, RET, and ALK found ORRs of
26%, 24%, 17%, 16%, 12%, 7%, 6%, 0%, respectively,
with single-agent anti-PD-(L)1.54 Combination regimens
involving ICIs and epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) are not
routinely used as severe hepatotoxicity leading to treatment discontinuation was seen in early-stage trials.55 56
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ICI treatment has been demonstrated to offer improved
outcomes to patients with EGFR mutant NSCLC after
disease progression on first-line TKIs in retrospective57
and prospective trials21 (IMpower150 is discussed in
more detail in the Tumors unselected by PD-L1 expression section). However, caution is warranted when ICIs
are administered sequentially after TKIs as there may be
increased risk for toxicity. A database study that included
20,516 participants with NSCLC in the US FDA Adverse
Event Reporting System found significantly higher rates
of immune-related pneumonitis for patients treated with
both an EGFR TKI and nivolumab (adjusted OR for interaction 4.31; 95% CI 2.37 to 7.86; p<0.001).58
Chemotherapy regimens are also used to treat NSCLC,59
although targeted therapies and immunotherapy have
shown better efficacy in specific patient subgroups (eg,
targeted therapy for those with alterations in driver oncogenes). A number of ICIs have been approved by the
FDA for the treatment of NSCLC in the first-line, maintenance, adjuvant, and R/R settings. Data from key clinical
trials that supported the FDA approvals of immunotherapies for NSCLC are summarized in table 2, and discussed
in more detail in the following paragraphs, organized by
tumor PD-L1 expression.
Tumors with PD-L1 expression ≥50%
The approval of pembrolizumab as a first-
line monotherapy for patients with NSCLC was based on results from
the phase III, randomized, open-
label KEYNOTE-
024
and KEYNOTE-
042 trials (KEYNOTE-
042 is discussed
in the Tumors with PD-L1 expression ≥1% section).30
KEYNOTE-
024 (NCT02142738) enrolled patients with
untreated, metastatic NSCLC and PD-
L1 TPS ≥50%
to receive either pembrolizumab or a platinum-
based
chemotherapy regimen. Patients assigned to the pembrolizumab arm had higher ORR, longer median OS and
extended median PFS compared with the chemotherapy
arm. The median duration of response (DOR) was not
reached at the time of writing in the pembrolizumab
arm versus 6.3 months for the chemotherapy arm.60 The
toxicity profile was favorable for immunotherapy, where
76.6% of patients in the pembrolizumab arm developed
treatment-related adverse events (TRAEs) compared with
90.0% of patients in the chemotherapy arm, 31.2% and
53.3% of which were grade 3–5 TRAEs, respectively.61
Long-term efficacy results in the intention-to-treat (ITT)
population show a 5-
year OS rate of 31.9% (95% CI
24.5% to 39.5%) with pembrolizumab versus 16.3% (95%
CI 10.6% to 23.0%) for chemotherapy.62 While the results
of KEYNOTE-024 lead to the initial approval of pembrolizumab monotherapy as a first-line option for patients
with NSCLC and PD-L1 TPS ≥50% in October 2016, this
indication was later expanded to tumors with TPS ≥1%
based on results from KEYNOTE-042 (discussed in the
Tumors with PD-L1 expression ≥1% section).
Approval for atezolizumab monotherapy for first-line
systemic therapy of metastatic PD-
L1-
positive disease
was based on the phase III, randomized, open-label trial
6

IMpower110 (NCT02409342).33 An interim analysis of
the 572 chemotherapy-naïve patients who were enrolled
and randomized to atezolizumab versus chemotherapy
found benefit in median OS for patients in the PD-L1-
high categories by the SP142 assay (PD-L1 staining on
TCs ≥50% or ICs ≥10%). TRAEs occurred in 90.2% of
patients in the atezolizumab arm and 94.7% of patients in
the chemotherapy arm, and grade 3–4 TRAEs occurred
in 30.1% and 52.5% of patients in the respective treatment arms.34 The FDA granted approval for atezolizumab
monotherapy for the first-line treatment of NSCLC for
patients with tumors that have high PD-L1 expression and
no EGFR/ALK alterations in May 2020.33
Cemiplimab has also received approval as a first-line
monotherapy for the treatment of patients with locally
advanced (not eligible for surgery or definitive chemoradiation) or metastatic NSCLC tumors that do not harbor
EGFR, ALK, or ROS1 genetic alterations with PD-
L1
TPS ≥50%.37 Approval in February 2021 was based on
results of the phase III, open-label EMPOWER-Lung 1
study, which enrolled patients with a history of smoking
to receive either cemiplimab or SOC chemotherapy.
Patients receiving cemiplimab experienced significantly
better OS and PFS compared with chemotherapy regimens. An exploratory analysis that stratified patients by
PD-L1 expression (PD-L1 ≥90%; PD-L1 >60% to <90%;
PD-L1 ≥50% to ≤60%) found that PD-
L1 expression
correlated with degree of change to tumor size, as well as
with incremental improvements in OS, PFS, and ORR.11
The decision to offer ICI as monotherapy or in combination with chemotherapy for patients with tumor PD-L1
expression 1%–49% is an ongoing area of controversy.
Patient-related factors such as ability to tolerate chemotherapy may contribute to the decision to offer ICI
monotherapy, while high disease burden disease-related
symptoms may necessitate the addition of chemotherapy
for rapid response induction. Improved ORR, OS and
PFS with immunotherapy−chemotherapy combinations compared with anti-PD-(L)1 monotherapy among
patients with baseline bone, brain, liver, and adrenal
metastases have been observed in retrospective real-world
analyses.63 A recent exploratory analysis of pooled data
from eight randomized controlled first-line NSCLC trials
enrolling patients with PD-L1 expression 1%–49% found
generally longer OS and PFS with anti-PD-(L)1 therapy
in combination with chemotherapy compared with
the monotherapy across most age, Eastern Cooperative
Oncology Group (ECOG) performance status (PS), and
smoking status subgroups. Only patients of age ≥75 had
similar outcomes with monotherapy versus combination
treatment.64
Tumors with PD-L1 expression ≥1%
Ipilimumab was approved for use in combination with
nivolumab based on data from the phase III, randomized, open-label CheckMate 227 (NCT02477826) trial. In
the study, patients were randomized 1:1:1:1 to one of four
arms (nivolumab, nivolumab with ipilimumab, nivolumab
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Table 2 Pivotal trial outcomes data for US Food and Drug Administration-approved immunotherapies for NSCLC
Results
Trial

Line of therapy

Median
DOR

Interventions

ORR

OS

Median PFS

Atezolizumab

38.3% (95% CI
29.1% to 48.2%)

NE

Median OS: 20.2 months 8.1 months (95% CI) (HR
(95% CI 16.5 to NE) (HR vs chemotherapy 0.63;
vs chemotherapy 0.59;
95% CI 0.45 to 0.88)
95% CI 0.40 to 0.89;
p=0.01)

Platinum-based
chemotherapy

28.6% (95% CI
19.9% to 38.6%)

6.7 months

Median OS: 13.1 months 5.0 months
(95% CI 7.4 to 16.5)

Pembrolizumab

44.8% (95% CI
36.8% to 53.0%)

NR

Median OS: 30.0 months
(95% CI 18.3 to NR) (HR
vs chemotherapy 0.63;
95% CI 0.47 to 0.86;
p=0.002)

Chemotherapy

27.8% (95% CI
20.8% to 35.7%)

6.3 months

Median OS: 14.2 months 6.0 months (95% CI 4.2
(95% CI 9.8 to 19.0)
to 6.2)

Cemiplimab

39% (95% CI
16.7 months
34% to 45%) (OR (95% CI 12.5
vs chemotherapy to 22.8)
2.53; 95% CI 1.74
to 3.69; p<0.0001)

Median OS: NR (95%
CI 17.9 to NE) (HR vs
chemotherapy 0.57;
95% CI 0.42 to 0.77;
p=0.0002)

Chemotherapy

20% (95% CI
16% to 26%)

6.0 months
(95% CI 4.3
to 6.5)

Median OS: 14.2 months 5.7 months (95% CI 4.5
(95% CI 11.2 to 17.5)
to 6.2)

Nivolumab + ipilimumab

35.9% (95% CI
31.1% to 40.8%)

23.2 months 24-month OS:
(95% CI 15.2 40.1% (HR vs
to 32.2)
chemotherapy 0.79;
97.72% CI 0.65 to 0.96;
p=0.007)

5.1 months (95% CI
4.1 to 6.3) (HR vs
chemotherapy 0.82; 95%
CI 0.69 to 0.97)

Platinum doublet
chemotherapy

30.0% (95% CI
25.5% to 34.7%)

6.2 months
(95% CI 5.6
to 7.4)

5.6 months (95% CI 4.6
to 5.8)

Pembrolizumab

27% (95% CI
24% to 31%)

20.2 months Median OS: 16.7 months
(95% CI 16.6 (95% CI 13.9 to 19.7)
to NR)
(HR vs chemotherapy
0.81; 95% CI 0.71 to
0.93; p=0.0018)

Chemotherapy

27% (95% CI
23% to 30%)

8.3 months
(95% CI 6.5
to 11.1)

Median OS: 12.1 months 6.6 months (95% CI 6.3
(95% CI 11.3 to 13.3)
to 7.3)

Pembrolizumab

18% (95% CI
14.1% to 22.5%)

NR (IQR
4.2 to 10.5
months)

36-month OS: 22.9%
(95% CI 19.8% to
26.1%) (HR vs docetaxel
0.69; 95% CI 0.60 to
0.80; p<0.00001)

Docetaxel

9.3% (95% CI
6.5% to 12.9%)

6 months
(IQR 2.7 to
6.1)

4.1 months (95% CI 3.8
36-month OS: 11.0%
(95% CI 7.9% to 14.7%) to 4.5)

Tumors with PD-L1 expression ≥50%
IMpower110
(NCT02409342)34

KEYNOTE-024
(NCT02142738)60 61

EMPOWER-Lung 1
(NCT03088540)11

First-line

First-line

First-line

10.3 months (95%
CI 6.7 to NR) (HR vs
chemotherapy 0.50; 95%
CI 0.37 to 0.68; p<0.001)

8.2 months (95% CI
6.1 to 8.8) (HR vs
chemotherapy 0.54;
95% CI 0.43 to 0.68;
p<0.0001)

Tumors with PD-L1 expression ≥1%
CheckMate 227
(NCT02477826)35

KEYNOTE-042
(NCT02220894)8 178

KEYNOTE-010*
(NCT01905657)7 67

First-line

First-line

Second-line

24-month OS: 32.8%

5.4 months (95% CI
4.3 to 6.2) (HR vs
chemotherapy 1.05; 95%
CI 0.93 to 1.19)

4.0 months (95% CI 3.1
to 4.1) (HR vs docetaxel
0.83; 95% CI 0.72 to
0.96; p<0.005)

Tumors unselected by PD-L1 expression
IMpower150†
(NCT02366143)21 70

First-line

Atezolizumab + paclitaxel + 40.6% (95% CI
8.3 months‡ 24 month OS: 38.3%
carboplatin‡
35.8% to 45.6%)‡
(95% CI 31.9% to
44.8%) (HR vs BCP
0.85; 95% CI 0.71 to
1.03)‡

6.7 months (95% CI 5.7
to 6.9) (HR vs BCP 0.91;
95% CI 0.78 to 1.06)‡

Atezolizumab +
bevacizumab +
paclitaxel + carboplatin

63.5% (95% CI
58.2% to 68.5%)

9.0 months

24-month OS: 43.4%
(95% CI 36.9% to
49.9%) (HR vs BCP
0.78; 95% CI 0.64 to
0.96; p=0.02)

8.3 months (95% CI 7.7
to 9.8) (HR vs BCP 0.62;
95% CI 0.52 to 0.74;
p<0.001)

Bevacizumab + paclitaxel + 48.0% (95% CI
carboplatin (BCP)
42.5% to 53.6%)

5.7 months

24-month OS: 33.7%
(95% CI 27.4% to
40.0%)

6.8 months (95% CI 6.0
to 7.1)

Continued
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Table 2 Continued
Results
Median
DOR

Trial

Line of therapy

Interventions

ORR

OS

Median PFS

IMpower130 †
(NCT02367781)6

First-line

Atezolizumab + nab-
paclitaxel + carboplatin

49.2% (95%
CI 44.5% to
54.0%) (OR vs
nab-paclitaxel +
carboplatin 2.07;
95% CI 1.48 to
2.89)

8.4 months
(95% CI 6.9
to 11.8)

24-month OS: 39.6%
(95% CI 33.6%
to 45.7%) (HR vs
chemotherapy 0.79;
95% CI 0.64 to 0.98;
p=0.033)

7.0 months (95% CI
6.2 to 7.3) (HR vs
chemotherapy 0.64;
95% CI 0.54 to 0.77;
p<0.0001)

Nab-paclitaxel + carboplatin 31.9% (95% CI
25.8% to 38.4%)

6.1 months
(95% CI 5.5
to 7.9)

24-month OS: 30.0%
(95% CI 21.7% to
38.2%)

5.5 months (95% CI 4.4
to 5.9)

Atezolizumab

14.6% (95% CI
11.4% to 18.3%)

16.3 months 24 month OS: 30.9%
(95% CI 10.0 (HR vs docetaxel 0.75;
to 26.3)
95% CI 0.64 to 0.89;
p=0.0006)

2.8 months (95% CI 2.6
to 3.0) (HR vs docetaxel
0.93; 95% CI 0.80 to
1.08; p=0.3495)

Docetaxel

13.4% (95% CI
10.3% to 17.0%)

6.2 months
(95% CI 4.9
to 8.4)

4.0 months (95% CI 3.3
to 4.2)

Nivolumab + ipilimumab +
chemotherapy

38.2% (95% CI
33.2% to 43.5%)

11.3 months Median OS: 15.6 months
(95% CI 8.5 (95% CI 13.9 to 20.0)
to NR)
(HR vs chemotherapy
0.66; 95% CI 0.55 to
0.80; p=0.0006)

Chemotherapy

24.9% (95% CI
20.5% to 29.7%)

5.6 months
(95% CI 4.4
to 7.5)

Nivolumab

19% (95% CI
23.8 months
16% to 24%) (OR (95% CI 11.4
vs docetaxel 1.91; to 36.1)
95% CI 1.28 to
2.86)

36-month OS:
17% (95% CI 14% to
21%) (HR vs docetaxel
0.70; 95% CI 0.61 to
0.81)

Docetaxel

11% (95% CI 8%
to 15%)

5.6 months
(95% CI 4.4
to 7.0)

36-month OS: 8% (95% 3.52 months (95% CI
CI 6% to 11%)
3.15 to 4.21)

Pembrolizumab +
chemotherapy

48.0% (95% CI
43.1% to 53.0%)

12.4 months 24-month OS: 45.5%
(HR vs chemotherapy
0.56; 95% CI 0.45 to
0.70)

9.0 months (95% CI
8.1 to 9.9) (HR vs
chemotherapy 0.48; 95%
CI 0.40 to 0.58)

Chemotherapy

19.4% (95% CI
14.2% to 25.5%)

7.1 months

24-month OS: 29.9%

4.9 months (95% CI 4.7
to 5.5)

Pembrolizumab +
chemotherapy

62.6% (95% CI
56.6% to 68.3%)

8.8 months

Median OS: 17.1 months
(95% CI 14.4 to 19.9)
(HR vs chemotherapy
0.71; 95% CI 0.58 to
0.88)

8.0 months (95% CI
6.3 to 8.4) (HR vs
chemotherapy 0.57; 95%
CI 0.47 to 0.69)

Chemotherapy

38.4% (95% CI
32.7% to 44.4%)

4.9 months

Median OS: 11.4 months 5.1 months (95% CI 4.3
(95% CI 10.1 to 13.7)
to 6.0)

Durvalumab

30.0% (95% CI
25.8% to 34.5%)
(p<0.001 vs
placebo)

NR (95% CI 36-month OS: 57.0%
27.4 months (95% CI 52.3% to
to NR)
61.4%) (unstratified HR
vs placebo 0.67; 95% CI
0.54 to 0.84)

17.2 months (95% CI
13.1 to 23.9) (HR vs
placebo 0.51; 95% CI
0.41 to 0.63)

Placebo

17.8% (95% CI
13.0% to 23.6%)

18.4 months 36-month OS: 43.5%
(95% CI 6.7 (95% CI 37.0% to
to 24.5)
49.9%)

5.6 months (95% CI 4.6
to 7.7)

OAK§ (NCT02008227)73

CheckMate 9LA
(NCT03215706)12

CheckMate 017
(NCT01642004) and
CheckMate 057¶
(NCT01673867)74

KEYNOTE-189
(NCT02578680)9

KEYNOTE-407
(NCT02775435)69

PACIFIC
(NCT02125461)**4 76

Second-line

First-line

Second-line

First-line

First-line

Maintenance

24-month OS: 21.1%

6.7 months (95% CI
5.6 to 7.8) (HR vs
chemotherapy 0.68; 95%
CI 0.57 to 0.82)

10.9 months (95% CI 9.5 5.0 months (95% CI 4.3
to 12.6)
to 5.6)
2.56 months (95% CI
2.20 to 3.48) (HR vs
docetaxel 0.80; 95% CI
0.69 to 0.92)

*ORR and DOR data are from patients treated with 2 mg/kg pembrolizumab. OS and PFS data are from updated pooled analyses including 2 mg/kg and 10 mg/kg doses.
†Study included patients with EGFR/ALK mutant tumors; ITT-wild–type population (no EGFR/ALK genetic alterations) data reported.
‡Updated analysis (January 2018) of ITT population (which includes patients with EGFR/ALK genetic alterations who had progression with, or intolerance to, at least one TKI).
§Primary efficacy population (ITT-850) data reported.
¶Pooled population from CheckMate 017 and Checkmate 057 reported.
**Approval is for stage III, unresectable NSCLC.
DOR, duration of response; ITT, intention-to-treat; NE, not estimable; NR, not reached; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1,
programmed death-ligand 1; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.

with chemotherapy, and chemotherapy). PD-L1-postive
patients (TPS ≥1%) in the nivolumab with ipilimumab
arm exhibited higher OS than those in the chemotherapy
8

arm at 24 months (40.1% vs 32.8%, respectively). Patients
developed TRAEs at a rate of 76.7% (32.8% developed
grade 3–4 TRAEs) versus 81.9% (36.0% developed grade
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3–4 TRAEs) in the nivolumab with ipilimumab arm versus
the chemotherapy arm, respectively.35 Based on OS data
from this trial, the FDA approved nivolumab with ipilimumab for first-line treatment of PD-L1-positive (TPS ≥1%)
NSCLC with no EGFR/ALK alterations.3 23 CheckMate
227 stratified patients by histology, and exploratory analysis with 4 years of follow-up found pronounced clinical
benefit with ipilimumab plus nivolumab compared with
chemotherapy among the 46 patients with squamous
NSCLC in the study. The 4-
year OS rate for patients
with squamous NSCLC treated with ipilimumab plus
nivolumab was 22% compared with 7% for chemotherapy
(median OS 15.9 months vs 8.5 months; HR=0.53; 95%
CI 0.34 to 0.84).5 Post-hoc analyses of CheckMate 227
demonstrated a trend toward more pronounced clinical
benefit with ipilimumab plus nivolumab for patients with
baseline brain metastases. Median OS was 18.8 months
for patients with brain metastases (95% CI 9.2 to 29.4)
versus 17.1 months for patients without brain metastases
(95% CI 15.3 to 19.9). The OS HR for nivolumab plus
ipilimumab versus chemotherapy for patients with brain
metastases was 0.57 (95% CI 0.38 to 0.85) versus 0.76
(95% CI 0.66 to 0.88) for patients without brain metastases.65 The combination of ipilimumab plus nivolumab
was not FDA-approved for these specific patient populations at the time of manuscript preparation, nor for the
treatment of patients with tumor PD-L1 expression ≤1%.
Prospective trials are needed to establish clinical benefit
in these populations.
Pembrolizumab monotherapy was FDA-approved as a
first-line treatment for PD-L1-positive (TPS ≥1%) NSCLC
without EGFR or ALK alterations in April 2019 for patients
with metastatic disease or those who have stage III disease
and are not candidates for surgery or radiation based
on results from the KEYNOTE-
042 (NCT02220894)
and KEYNOTE-
024 (NCT02142738; KEYNOTE-
024 is
discussed in the Tumors with PD-L1 expression ≥50%
section) trials, both of which were phase III, randomized, and open-label.30 In KEYNOTE-042, patients with
TPS ≥1% who were treated with pembrolizumab had
significantly higher median OS compared with those
receiving platinum-
based chemotherapy. TRAEs were
observed in 63% of patients receiving pembrolizumab
(18% developed grade 3–5 TRAEs) and in 90% of
patients receiving chemotherapy (41% developed grade
3–5 TRAEs).8
Pembrolizumab was initially granted an accelerated
approval from the FDA for the treatment of patients
with R/R NSCLC (who have disease progression on or
after platinum-
containing chemotherapy or targeted
therapy against ALK or EGFR, if appropriate) with PD-L1
TPS ≥50% in October 2015. This approval was based off
of results from the phase I, open-label KEYNOTE-001
(NCT01295827) trial, in which pembrolizumab-treated
patients with NSCLC and high PD-L1 expression experienced durable responses (ORR 41% (95% CI 28.6% to
54.3%)) and a tolerable safety profile.66 In the phase II/III,
randomized, open-label KEYNOTE-010 (NCT01905657)

trial, multiple dosing regimens of pembrolizumab were
compared against docetaxel in the R/R (after platinum-
based chemotherapy) NSCLC setting. The trial enrolled
1033 patients with PD-L1-positive disease (TPS ≥1%) to
receive pembrolizumab at either 2 mg/kg every 3 weeks or
10 mg/kg every 3 weeks, or chemotherapy. Patients in the
2 mg/kg pembrolizumab arm (current clinical dosing)
had significantly higher median OS at 10.4 months (95%
CI 9.4 to 11.9; HR 0.71 (95% CI 0.58 to 0.88; p=0.0008))
for pembrolizumab versus 8.5 months (95% CI 7.5 to
9.8) for docetaxel. Across all dosages pembrolizumab
was associated with significantly higher OS at 36 months,
ORR, and DOR—the pembrolizumab arms had not
reached median DOR at the time of manuscript preparation, while median DOR was 6 months in the docetaxel
arm.7 Long-term safety data have also been reported, with
a median follow-up of 42.6 months (range 35.2–53.2); in
the pembrolizumab arms, patients developed TRAEs at
a rate of 67.7% (16.1% developed TRAEs of grade 3–5),
and in the docetaxel arm patients developed TRAEs at a
rate of 82.5% (36.6% developed TRAEs of grade 3–5).
Notably, 14 patients received second courses of pembrolizumab after PFS events, which led to a partial response
in six patients (43%) and stable disease in five patients
(36%).67 The full approval of pembrolizumab in this
setting was expanded to include patients with tumors with
PD-L1 TPS ≥1% in October 2016.68
Tumors unselected by PD-L1 expression
During the phase III, randomized, quadruple-
masked
study KEYNOTE-189 (NCT02578680), 616 patients were
assigned to receive pembrolizumab with chemotherapy
(pemetrexed and platinum) or chemotherapy alone as a
first-line treatment for non-squamous NSCLC. Pembrolizumab treatment was associated with improved ORR,
DOR, milestone OS at 24 months, and median PFS. All-
cause adverse events (AEs) occurred in 99.8% of patients
receiving pembrolizumab (71.9% of patients developed
AEs of grade 3–5) and in 99.0% of patients receiving
chemotherapy alone (66.8% of patients developed
AEs of grade 3–5).9 Benefit with pembrolizumab plus
chemotherapy was maintained across PD-L1 expression
cutpoints and regardless of the presence of baseline liver
or brain metastases.9 Based on KEYNOTE-189, the FDA
approved the use of pembrolizumab with pemetrexed
and platinum chemotherapy for first-line treatment of
non-squamous NSCLC with no EGFR/ALK genetic alterations in May 2017.30
In KEYNOTE-407 (NCT02775435), 559 patients with
squamous NSCLC were assigned to receive pembrolizumab with chemotherapy (carboplatin and paclitaxel
or nab-paclitaxel) or chemotherapy alone in a phase III,
randomized, triple-masked clinical trial. In the protocol-
specified final analysis, patients in the pembrolizumab arm
had a higher ORR, median DOR, median OS, and median
PFS. Patients in the pembrolizumab arm developed AEs
at a rate of 98.6%, with 74.1% developing AEs of grade
3–5. OS and PFS benefit for the ICI plus chemotherapy
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combination was maintained across prespecified PD-L1
expression subgroups, with an OS HR of 0.61 (95% CI
0.38 to 0.98) for patients with PD-L1-negative tumors,
0.57 (95% CI 0.36 to 0.90) for patients with tumor PD-L1
expression 1%–49%, and 0.64 (95% CI 0.37 to 1.10) for
patients with tumor PD-L1 expression ≥50%. Patients in
the chemotherapy alone arm developed AEs at a rate of
98.2%, and 69.6% developed AEs of grade 3–5.69 The FDA
approved pembrolizumab with carboplatin and paclitaxel
or nab-paclitaxel for the first-line treatment of metastatic,
squamous NSCLC in May 2017.30
The FDA has also approved atezolizumab in combinations with cytotoxic and targeted therapies for the first-line
treatment of metastatic NSCLC. In the phase III, randomized, open-
label IMpower150 trial (NCT02366143),
1202 patients were assigned to receive atezolizumab,
carboplatin, and paclitaxel (ACP); atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP); or bevacizumab, carboplatin, and paclitaxel (BCP). As described
in table 2, the ABCP arm had higher ORR, DOR, OS,
and PFS compared with the BCP arm in the ITT-wild-type
(no EGFR/ALK alterations) population.70 Although statistically significant OS benefit with ABCP compared with
BCP was demonstrated in the ITT population, exploratory
analyses revealed longer median OS with ABCP and ACP
versus BCP in PD-L1-high and PD-L1-positive subgroups,
whereas median OS was similar with ACP and ABCP
versus BCP in patients with PD-L1-negative tumors.71 The
ACP arm, in contrast, did not exhibit marked clinical
advantages over the BCP arm in secondary analyses of
the ITT population (including patients with EGFR/ALK
genetic alterations who had progression with, or showed
intolerance to at least one approved TKI). Importantly,
ABCP was also associated with improved OS compared
with BCP in the subgroup of patients with tumors with
EGFR mutations (median OS not estimable with ABCP vs
median OS 17.5 months with BCP; HR 0.31; 95% CI 0.11
to 0.83).21 Patients developed grade 3–4 AEs at a rate of
64% in the ABCP group and at 58% in the BCP group.21
The FDA approved the ABCP combination regimen for
the first-line treatment of metastatic NSCLC in December
2019.33
During IMpower130 (NCT02367781), a phase
III, randomized, open-
label trial of patients with
chemotherapy-
naïve non-
squamous NSCLC, atezolizumab with chemotherapy (nab-
paclitaxel and carboplatin) was compared with chemotherapy alone. Patients
in the atezolizumab arm with no EGFR/ALK alterations
(ITT wild-type population) had longer median OS, long-
term (24-month) OS, median PFS, ORR, and median
DOR. No difference in OS was seen across pre-stratifed
PD-L1 expression subgroups. TRAEs were observed in
96% of patients in the atezolizumab arm and 93% of
patients in the chemotherapy alone arm, with 75% of
patients receiving atezolizumab with chemotherapy and
61% of patients receiving chemotherapy developing
grade 3–5 TRAEs.6 In December 2018, the FDA approved
atezolizumab with nab-paclitaxel and carboplatin for the
10

first-line treatment of metastatic NSCLC with no EGFR/
ALK alterations.33
The CheckMate 9LA trial (NCT03215706), a phase III,
randomized, open-label study, compared nivolumab and
ipilimumab plus 2 cycles of platinum doublet chemotherapy versus platinum doublet chemotherapy alone
in 719 patients with recurrent or metastatic NSCLC with
no EGFR or ALK mutations. ORR was increased in the
ICI-treated arm, as well as DOR, median OS, and median
PFS. The 2-year OS rates were 38% and 26% for the ICI
arm and the chemotherapy arm, respectively. Median OS
was similar for the PD-L1 expression ≥1% group and the
PD-L1 expression <1% group, at 15.8 months and 16.8
months, respectively (HR vs chemotherapy 0.64 (95%
CI 0.50 to 0.82) for PD-L1 expression ≥1%; HR versus
chemotherapy 0.62 (95% CI 0.45 to 0.85) for PD-
L1
expression <1%). TRAEs of grade 3–4 were reported in
47% of patients receiving ICIs versus 38% of patients
receiving chemotherapy alone.12 In May 2020, the FDA
approved nivolumab and ipilimumab plus 2 cycles of platinum doublet chemotherapy for the first-line treatment
of NSCLC with no EGFR or ALK alterations.3 23
Atezolizumab has also showed benefit in clinical trials
for R/R (after platinum-based chemotherapy) NSCLC.
In the phase III, randomized, open-
label OAK trial
(NCT02008227), patients were assigned to receive either
docetaxel or atezolizumab.72 In the primary efficacy population (n = 850), patients treated with atezolizumab had
higher median OS, milestone (24-month) OS, and higher
median DOR, although there was not a statistically significant advantage in PFS or ORR. The secondary efficacy
population, which included 1,225 patients, had results
consistent with the primary population. Patients receiving
atezolizumab developed TRAEs at a rate of 64.0% (14.9%
developed grade 3–5 TRAEs), while patients receiving
docetaxel developed TRAEs at a rate of 86.2% (42.4%
developed grade 3–5 TRAEs).73 Data from OAK led to
the approval of atezolizumab for R/R NSCLC in patients
who have received prior chemotherapy and EGFR/ALK
targeted treatment, if appropriate, in April 2017.33
Nivolumab was the first anti-
PD(L)−1 agent to be
approved in lung cancer. In March 2015, the FDA
approved nivolumab for the treatment of metastatic
squamous NSCLC with progression on or after platinum-
based chemotherapy based on CheckMate 017 and
CheckMate 063. In October 2015, nivolumab’s indication
was expanded to the treatment of metastatic NSCLC with
progression on or after platinum-
based chemotherapy
based on results of CheckMate 057 with patients with
metastatic non-squamous NSCLC.3 In a pooled analysis
of CheckMate 017 (NCT01642004; patients with squamous NSCLC) and CheckMate 057 (NCT01673867;
patients with non-
squamous NSCLC), patients treated
with nivolumab exhibited improvements in ORR,
median DOR, 36-month OS, and 3-year PFS rates (10%
versus <1%; HR 0.80; 95% CI 0.69 to 0.92) compared with
patients who received docetaxel.74 At 5-year update, the
OS rates (13.4% vs 2.6%), and PFS rates (8% vs 0%; HR
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0.79; 95% CI 0.68 to 0.92), continued to favor immunotherapy. No patients were treated with docetaxel for more
than 2 years, however, at 5 years, 67.9% of the patients
who received nivolumab experienced any grade TRAEs,
with 10.9% being grade 3–4 events.75
Unresectable stage III NSCLC
Durvalumab, an anti-PD-L1 antibody, has been approved
for use as a consolidation therapy in patients with stage III
unresectable disease following concurrent chemoradiotherapy who have not yet experienced disease progression.
During the phase III, randomized, quadruple-
masked
PACIFIC trial (NCT02125461), patients were assigned
to receive durvalumab or placebo following chemoradiation therapy. Patients who received durvalumab experienced greater median OS, milestone (36-month) OS,4
and higher median PFS. AEs were reported in 96.8% of
patients receiving durvalumab (30.5% developed AEs of
grade 3–5) and in 94.9% of patients receiving placebo
(26.1% developed AEs of grade 3–5).76 OS improvements
were seen across most PD-L1 expression subgroups (HR
for TC ≥25% = 0.50, 95% CI 0.30 to 0.83; HR for TC <25%
= 0.89, 95% CI 0.63 to 1.25; HR for TC ≥1% = 0.59, 95%
CI 0.41 to 0.83; HR for TC 1%–24% = 0.67, 95% CI 0.41 to
1.10; HR for unknown PD-L1=0.60, 95% CI 0.43 to 0.84),
with the exception of patients with tumor PD-L1 expression <1% (HR=1.14, 95% CI 0.71 to 1.84).77 Durvalumab
was approved as a maintenance therapy in this setting by
the FDA in February of 201878 and approved by the European Medicines Agency for consolidation therapy for
patients with PD-L1 positive tumors in October of 2018.
Pembrolizumab is also indicated as a first-line treatment
for patients with stage III NSCLC (for patients not eligible
for surgery or definitive chemoradiation),8 discussed in
the Tumors with PD-L1 expression ≥1% section.
Resectable stage II to IIIA NSCLC
The FDA approved atezolizumab as an adjuvant treatment
following resection and platinum-
based chemotherapy
for patients with stage II to IIIA NSCLC whose tumors
have PD-L1 expression on ≥ 1% of TCs on October 15,
2021. The SP263 assay was approved as a companion diagnostic test with the new indication. Approval was based
on IMpower010, a randomized, multicenter, open-label,
phase III trial comparing 16 cycles of adjuvant atezolizumab (1200 mg every 21 days) or best supportive care
after tumor resection and completion of 1–4 cycles of adjuvant platinum-based chemotherapy. Investigator-assessed
disease-free survival (DFS) was the primary endpoint. At
a median follow-up of 32.2 months (IQR 27.4–38.3), the
primary endpoint was met for all patients with stage II−
IIIA disease. DFS events occurred in 173 (39%) of the 442
patients with stage II−IIIA tumors receiving atezolizumab
and 198 (45%) of the 440 in the group receiving best
supportive care, leading to an HR of 0.79 (95% CI 0.64 to
0.96; p=0.020). In the subgroup with stage II−IIIA tumors
with PD-L1 expression ≥1%, 88 (35%) of 248 patients
receiving atezolizumab and 105 (46%) of 228 patients

receiving best supportive care group experienced DFS
events for a stratified HR of 0.66 (95% CI 0.50 to 0.88;
year DFS rates for all patients were
p=0.0039). The 3-
56% in the atezolizumab group versus 49% in the best
supportive care group and among patients with tumors
with PD-L1 expression ≥1% the 3-year DFS rates were
60% and 48%, respectively. For the secondary endpoint
of DFS in patients with tumor PD-L1 on 50% or more
of TCs, the unstratified HR was 0.43 (95% CI 0.27 to
0.68) and post-hoc exploratory analyses demonstrated an
unstratified HR of 0.87 (95% CI 0.60 to 1.26) for patients
with tumors PD-L1 expression of 1%–49%. OS data were
immature at the cut-off date. Atezolizumab-related grade
3 and 4 AEs occurred in 11% of patients (n=53 of 495)
and there were 4 grade 5 events.79
Nivolumab in combination with platinum doublet
chemotherapy every 3 weeks for up to 3 cycles prior
to definitive surgery for adult patients with resectable
NSCLC gained FDA approval on March 4, 2022. Approval
was based on improvements in pCR rate and event-free
survival (EFS) compared with neoadjuvant platinum
doublet chemotherapy alone in the phase III, randomized, open-label trial CheckMate 816, which included a
total of 358 patients with with resectable, histologically
confirmed Stage IB (≥4 cm), II, or IIIA NSCLC (American Joint Commission on Cancer(AJCC)/Union for
International Cancer Control (UICC) staging criteria)
and measurable disease by Response Evaluation Criteria
in Solid Tumors (RECIST) v1.1. Significantly increased
pCR rates were observed for neoadjuvant nivolumab plus
chemotherapy compared with chemotherapy alone in
the ITT population (24.0% vs 2.2%; OR 13.94; 99% CI
3.49 to 55.75; p<0.0001) as well as across all key subgroups
including by disease stage (IB/II, 26.2% vs 4.8%; ≥IIIA,
23.0% vs 0.9%), PD-L1 expression status (PD-L1 <1%,
16.7% vs 2.6%; PD-L1 ≥1%, 32.6% vs 2.2%), and TMB
(TMB low, 22.4% vs 1.9%; TMB-H, 30.8% vs 2.7%).80
Neoadjuvant nivolumab plus chemotherapy did not
impede the feasibility of surgery nor increase surgical
complications. Definitive surgery rates were 83% with
nivolumab plus chemotherapy (n=149) compared with
75% with chemotherapy alone (n=135). An R0 resection was achieved in 83% patients in the nivolumab plus
chemotherapy arm compared with 78% of patients in the
chemotherapy alone arm and the median percentage
residual viable tumor cells in the primary tumor bed
were 10% and 74% across arms, respectively. Any-grade
surgery-related AEs were reported in 41% versus 47%
of patients in the nivolumab plus chemotherapy versus
chemotherapy alone arms, and grade 3–4 AEs were
reported in 11% versus 15% of patients in each arm,
respectively.81 Median EFS was 31.6 months (95% CI 30.2
to not reached) in the nivolumab plus chemotherapy arm
and 20.8 months (95% CI 14.0 to 26.7) in the chemotherapy alone arm.
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Panel recommendations
For patients with metastatic NSCLC with no actionable mutations and TPS ≥50%, the panel recommends first-
line pembrolizumab, atezolizumab, or
cemiplimab monotherapy, with consideration for
chemo-immunotherapy for patients with high tumor
disease burden or worrisome symptoms (LE:2).
► For patients with metastatic NSCLC with no actionable mutations and TPS <50%, pembrolizumab with
chemotherapy, atezolizumab with chemotherapy
(with or without bevacizumab), or nivolumab with
ipilimumab with or without 2 cycles of chemotherapy
(in select cases) should be used (LE:2).
► For patients with metastatic NSCLC with no actionable
mutations and tumor PD-L1 expression 1%–49% who
are ineligible for or refuse chemotherapy, pembrolizumab monotherapy may be considered (LE:2).
► For patients with metastatic NSCLC with tumor PD-L1
expression ≤1% and baseline brain metastases or
squamous histology nivolumab in combination with
ipilimumab may be considered (LE:3).
► For adult patients with resectable (tumors ≥4 cm or
node positive) NSCLC, nivolumab in combination
with platinum-doublet chemotherapy every 3 weeks
for 3 cycles in the neoadjuvant setting may be considered (LE:2).
► For adult patients with stage II to IIIA NSCLC and
PD-L1 expression ≥50%, atezolizumab is recommended as an adjuvant treatment following resection
and platinum-based chemotherapy (LE:2).
► For adult patients with stage II to IIIA NSCLC and
PD-
L1 expression 1%–49%, atezolizumab may be
considered as an adjuvant treatment following resection and platinum-based chemotherapy (LE:2).
► In patients with non-
squamous cell NSCLC tumors
positive for EGFR, ALK, or ROS1 alterations, appropriate FDA-
approved targeted therapy should be
administered as first-line therapy (LE:1).
► In patients with non-
squamous cell NSCLC tumors
positive for EGFR, ALK, or ROS1 alterations that
become refractory to TKIs, chemotherapy should be
given, with consideration for the addition of immunotherapy (LE:2) and antiangiogenic therapy.
► In patients with non-
squamous cell NSCLC with
tumors positive for actionable molecular alterations
other than EGFR, ALK, or ROS1 alterations, appropriate FDA-
approved targeted therapies can be
considered as first-line therapy.
► Whenever possible, patients should be offered participation in clinical trials.
A treatment algorithm for advanced NSCLC summarizing the panel recommendations is provided in figure 1.
The treatment landscape for patients with NSCLC
continues to evolve and there are a number of clinical
trials underway, including many late-stage, phase III trials
investigating additional ICIs and ICI combination therapies for the treatment of NSCLC.
►
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SMALL-CELL LUNG CANCER
The SOC for patients with SCLC has typically included
platinum-
based
chemotherapy
or
radiotherapy,
depending on disease staging (extensive-stage SCLC (ES-
SCLC) or limited-
stage SCLC).82 83 Recently, however,
a number of approvals have led to ICIs entering widespread clinical usage for the treatment of SCLC. Key data
from landmark trials leading to the approvals for ICIs in
SCLC are summarized in table 3. While there have been
two post-marketing withdrawals of ICIs that did not meet
their endpoints in subsequent studies after receiving
accelerated approval, immunotherapy at various stages of
disease and lines of therapy for the treatment of SCLC is
an active and ongoing area of investigation.
First-line treatment of SCLC
Atezolizumab in combination with carboplatin and
etoposide was approved for first-line therapy of SCLC
in March 2019, based on OS and DOR data from the
phase III, randomized, double-masked IMpower133 trial
(NCT02763579).33 In the study, among the 403 patients
randomized to receive atezolizumab with chemotherapy
(carboplatin and etoposide) or placebo with chemotherapy for previously untreated ES-
SCLC, the immunotherapy arm had longer OS and PFS than the control
group. Importantly, the toxicity frequencies were comparable across both groups: in the atezolizumab arm,
patients developed AEs at a rate of 94.9% with 58.1% of
grade 3–5, and in the chemotherapy alone arm the rate
was 92.3% with 57.6% of grade 3–5 (85).
Although prophylactic cranial irradiation (PCI) and/
or thoracic radiation consolidation are often offered
following completion of induction chemotherapy for
ES-SCLC,84 these approaches may become de-
emphasized as immunotherapy becomes incorporated into the
SOC.85 Thoracic radiation has been linked to increased
risk of developing immune-
related pneumonitis in
patients with NSCLC treated with anti-PD-(L)1.63 86 PCI
demonstrated no OS benefit compared with MRI surveillance in a randomized phase III trial that enrolled 224
patients with ES-SCLC, however, this study was performed
before ICIs were routinely used for any lung cancer indications.87 American Society for Radiation Oncology
(ASTRO) guidelines conditionally recommend consideration of offering PCI to ICI-
treated patients with
ES-SCLC,84 however, emerging evidence suggests that
immunotherapy treatment may offer comparable benefits against intracranial disease without risks of impaired
cognition associated with PCI. The incidence of brain
metastases was reduced among patients with NSCLC
receiving durvalumab consolidation in PACIFIC (6.3% vs
11.8%)4 and evidence from melanoma suggests that anti-
PD-1 (with or without anti-CTLA-4) has activity against
intracranial metastases.88 In IMpower133, a total of 44
patients (22 in each arm) received PCI on study and 7
patients (3 in immunotherapy arm and 4 in control arm)
were treated with thoracic radiation. The incidence of
central nervous system (CNS)-
related related adverse
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Figure 1 Advanced NSCLC immunotherapy treatment algorithm. Algorithm for the treatment of advanced NSCLC based on
the evidence- and consensus-based recommendations of the SITC Lung Cancer and Mesothelioma Clinical Practice Guideline
Expert Panel. In all cases, chemotherapy selection should be guided by histology. Whenever possible, patients should be
offered participation in clinical trials.
*Select patients with stage III NSCLC may also be considered for PD-L1 expression testing to determine eligibility
for adjuvant ICIs or predict clinical benefit in the unresectable setting in select cases. See the Diagnostics tests and
biomarkers and Non-small cell lung cancer sections for more information on approved immunotherapy treatment
options for stage III NSCLC.
†See the Contraindicated patient populations section for discussion of immunotherapy in special patient populations.
‡Comprehensive next-generation sequencing (NGS) is recommended for molecular testing. If NGS is not available,
tumor tissue should be tested for molecular driver genetic alterations.
§For PD-L1 expression assessment, the 22C3, 28–8, and SP263 assays are interchangeable. The SP142 assay is not
interchangeable and does not perform equivalently to the other assays listed.
Abbreviations: FDA, US Food and Drug Administration; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung
cancer; PD-L1, programmed death-ligand 1; SITC, Society for Immunotherapy of Cancer; TKI, tyrosine kinase inhibitor;
TPS, tumor proportion score.

events was similar between arms among the patients
who received PCI.8 Because data are sparse on the relative risks and benefits to patients when immunotherapy
and radiotherapy are used together, the only appropriate
setting for these modalities to be offered sequentially or
in combination is in a clinical trial.
Durvalumab was FDA-approved in March 2020, as a
first-
line treatment for ES-
SCLC, in combination with

etoposide and either carboplatin or cisplatin,78 based
on the phase III, randomized, open-
label CASPIAN
trial (NCT03043872). The 268 patients who received
durvalumab with chemotherapy exhibited a significant
advantage in median OS versus chemotherapy treatment
(269 patients) alone. Similar rates of AEs were reported
in both arms, with 98% for the durvalumab group and
97% for the chemotherapy group. Both arms reported
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Table 3 Pivotal trial outcomes data for US Food and Drug Administration-approved immunotherapies for small-cell lung
cancer
Results
Trial

Interventions

ORR

Median DOR

OS

Median PFS

Atezolizumab
+ carboplatin +
etoposide

60.2% (95%
CI 53.1% to
67.0%)

4.2 months

Median OS: 12.3
months (95% CI
10.8 to 15.9) (HR vs
chemotherapy 0.70;
95% CI 0.54 to 0.91;
p=0.007)

5.2 months (95% CI 4.4 to 5.6) (HR vs
chemotherapy 0.77; 95% CI 0.62 to 0.96; p
=0.02)

Placebo + carboplatin 64.4% (95%
+ etoposide
CI 57.3% to
71.0%)

3.9 months

Median OS: 10.3
months (95% CI 9.3
to 11.3)

4.3 months (95% CI 4.2 to 4.5)

First-line setting
IMpower133
(NCT02763579)179

CASPIAN (NCT03043872)89

Durvalumab +
(carboplatin or
cisplatin + etoposide)

68% (OR vs
5.1 months
chemotherapy
1.56; 95% CI
1.10 to 2.22)

Median OS: 13.0
months (95% CI
11.5 to 14.8) (HR vs
chemotherapy 0.73;
95% CI 0.59 to 0.91;
p=0.0047)

5.1 months (95% CI 4.7 to 6.2) (HR vs
chemotherapy 0.78; 95% CI 0.65 to 0.94)

Carboplatin or
cisplatin + etoposide

58%

Median OS: 10.3
months (95% CI 9.3
to 11.2)

5.4 months (95% CI 4.8 to 6.2)

5.1 months

DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

grade 3–5 AEs at a rate of 62%.89 Another arm of this trial
examined the durvalumab plus chemotherapy regimen
in combination with tremelimumab, an anti-CTLA-4 ICI,
but this combination did not meet the primary endpoint
of improved OS compared with the chemotherapy combination regimen.90
Pembrolizumab in combination with chemotherapy
has also been investigated in the first-line setting in the
randomized, double-
blind, phase III KEYNOTE-
604
trial (NCT03066778), which compared pembrolizumab plus etoposide and platinum-based therapy with
placebo plus etoposide and platinum-based therapy for
patients with ES-SCLC. The addition of pembrolizumab
to chemotherapy improved PFS compared with chemotherapy alone (median PFS 4.5 months vs 4.3 months, 12
month PFS 13.6% vs 3.1%; HR 0.75; 95% CI 0.61 to 0.91;
p=0.0023). Numerically superior OS was reported in the
pembrolizumab arm, however the prespecified threshold
for statistical significance was not met (median OS 10.8
months vs 9.7 months, 12 month OS 22.5% vs 11.2%; HR
0.80; 95% CI 0.64 to 0.98; p=0.0164).91
In the randomized, phase II ECOG-
ACRIN EA5161
(NCT03382561) trial, nivolumab in combination with
etoposide and platinum-
based therapy for first-
line
treatment of ES-SCLC demonstrated improved PFS (5.5
months vs 4.6 months with chemotherapy alone; HR 0.65;
95% CI 0.46 to 0.91; p=0.012) as well as OS (11.3 months
vs 8.5 months; HR 0.67; 95% CI 0.46 to 0.98; p=0.038) in
the ITT population. TRAEs grade 3–4 occurred in 77%
of the patients in the nivolumab plus chemotherapy arm
and 72% of patients in the chemotherapy arm.92
Treatment of relapsed/refractory SCLC
Both pembrolizumab and nivolumab were voluntarily
withdrawn from the market for the treatment of patients
14

with R/R SCLC after having received accelerated
approvals. The withdrawals occurred against a backdrop
of an industry-wide evaluation of accelerated approvals for
drugs that did not meet post-marketing requirements by
the FDA Oncologic Drugs Advisory Committee (ODAC).
Furthermore, there is currently no evidence supporting
the use of these two agents following the use of atezolizumab or durvalumab in the first-line setting.
In addition to the withdrawals of pembrolizumab and
nivolumab for R/R SCLC indications, in 2021, a public
meeting was held to discuss the status of six additional
accelerated approvals, during which SITC provided
real-
time coverage summarizing stakeholders’ positions (available at http://blog.sitcancer.org/2021/04/
sitc-meeting-report-april-27-fda-odac.html, http://blog.
sitcancer.org/2021/04/sitc-meeting-report-april-28-fda-
odac.html, and http://blog.sitcancer.org/2021/04/sitc-
meeting-report-april-29-fda-odac.html). Of note, when
additional studies are required for full approval, the
design of the subsequent studies need not necessarily
be identical to the indication for which the accelerated
approval was granted.
Previously, the FDA had granted accelerated approval
in August 2018 to nivolumab monotherapy for the treatment of patients with SCLC who experienced disease
progression after at least two lines of prior therapy,
including one platinum-based agent, based on response
rates and DORs from the phase I/II, randomized, open-
label Checkmate 032 study (NCT01928394),3 which
included a cohort of 109 patients with R/R SCLC.93 The
subsequent randomized CheckMate 331 trial showed
no OS benefit from second-
line nivolumab compared
with chemotherapy following first-
line platinum-
based
chemotherapy.94 Similar findings were observed in the
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maintenance phase after completion of first-line chemotherapy, where nivolumab, either alone or in combination with ipilimumab, did not show OS improvement
compared with placebo.95
Pembrolizumab was originally approved for the treatment of patients with metastatic SCLC with disease
progression on or after platinum-
based chemotherapy
and at least one other prior line of therapy based on
a pooled analysis of patients from the phase I, open-
label KEYNOTE-
028 (NCT02054806) and the phase
II, open-
label KEYNOTE-
158 (NCT02628067) trials
(including 131 patients from the SCLC cohorts in both
studies).30 96 Nevertheless, there were no clinical trials
comparing pembrolizumab to standard chemotherapy
in patients with previously treated SCLC. Furthermore,
as discussed in the First-line therapy for SCLC section,
first-
line pembrolizumab plus chemotherapy improved
PFS but not OS compared with chemotherapy alone in
KEYNOTE-604.91 In 2021, despite disease setting evaluated being in first-line rather than in previously treated
patients with SCLC, the outcomes of KEYNOTE-604 were
described as the rationale for the voluntary withdrawal
of the pembrolizumab indication for patients with metastatic SCLC with disease progression on or after platinum-
based chemotherapy and at least one other prior line of
therapy.97
Panel recommendations
Patients with ES-SCLC and no contraindication for
the use of ICIs should be treated with first-line carboplatin, etoposide, and atezolizumab or platinum-
based chemotherapy, etoposide, and durvalumab,
both during induction chemotherapy and as maintenance (LE:2).
► For patients with ES-SCLC following the completion of
induction chemotherapy plus ICI, PCI is not currently
recommended outside of a clinical trial setting.
► The use of thoracic radiation following completion
of induction chemotherapy plus ICI in patients with
ES-SCLC is not recommended outside of a clinical
trial setting.
► Whenever possible, patients should be offered participation in clinical trials.
►

MESOTHELIOMA
Mesothelioma can affect the mesothelium in any part of
the body, although it most commonly occurs in the pleura
surrounding the lungs (pleural mesothelioma). About
3,000 new cases are diagnosed in the US each year and
mesothelioma was the primary cause of death for 45,221
persons age ≥25 years from 1999 to 2015.98 99
Diagnosis and biomarkers
Prognostic factors that are associated with survival in
patients with pleural mesothelioma include performance
status, white blood cell count, gender, and sarcomatoid
subtype.100–102 While there have been efforts to identify molecular biomarkers of prognosis or response, no

biomarkers have been validated for clinical use, and
molecular biomarkers remain limited to research use at
this time. One gene, BRCA1-associated protein 1 (BAP1),
is commonly mutated in malignant mesothelioma.103
While BAP1 has not demonstrated utility as a prognostic
biomarker for mesothelioma,104 it is important to note
that germline pathogenic mutations in the BAP1 gene
predispose patients (or their relatives) to mesothelioma or other types of cancer (including uveal melanoma, cutaneous melanoma, renal cell carcinoma, and
meningiomas).105–107
First-line treatment of mesothelioma
Historically, the first-line treatment of mesothelioma has
consisted of chemotherapy, with regimens that include
combination pemetrexed and cisplatin with or without
bevacizumab.108 109 However, a new approval by the FDA
introduced dual immunotherapy as an option for the first-
line treatment of pleural mesothelioma in October 2020.
CheckMate 743 (NCT02899299), a phase III, randomized
open-label trial, assigned 605 patients with unresectable
malignant pleural mesothelioma to receive combination
nivolumab and ipilimumab or chemotherapy (pemetrexed with cisplatin or carboplatin).3 23 The median
OS was significantly increased for patients receiving
nivolumab plus ipilimumab versus chemotherapy at 18.1
months (95% CI 16.8 to 21.5) and 14.1 months (95%
CI 12.5 to 16.2), respectively (HR 0.74; 95% CI 0.61 to
0.89; stratified log-rank p=0.002). Notably, there was a
dramatic difference in OS between histological subtypes,
with patients with non-epithelioid mesothelioma experiencing a greater benefit from ICI therapy. While the
median OS in patients with epithelioid mesothelioma
was similar between the ipilimumab and nivolumab and
chemotherapy treatment groups at 18.7 months (95%
CI 16.9 to 22) versus 16.5 months (95% CI 14.9 to 20.5),
respectively, patients with non-epithelioid histology had
a median OS of 18.1 months (95% CI 12.2 to 22.8) with
ipilimumab and nivolumab and 8.8 months (95% CI 7.4
to 10.2) with chemotherapy.110 There was no significant
difference when comparing ICIs to chemotherapy in
median PFS (6.8 months vs 7.2 months), ORR (40% vs
43%), or median DOR (11.0 months vs 6.7 months). The
3-year duration of response rate was 28% with nivolumab
plus ipilimumab and 0% with chemotherapy. Any-grade
TRAEs occurred in 80% and 82% of the patients in the
nivolumab plus ipilimumab and chemotherapy arms,
respectively. Grade 3–4 TRAEs were experienced in 31%
of patients treated with nivolumab plus ipilimumab and
32% of patients treated with chemotherapy.111
Several ongoing clinical trials are determining the efficacy and safety of additional immunotherapies for patients
with pleural mesothelioma. These trials include ICI therapies, immunotherapy plus chemotherapy combinations
(such as durvalumab plus platinum-based chemotherapy,
which was associated with improved OS in the phase II
PrE0505 trial112) as well as chimeric antigen receptor
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(CAR) T cells, vaccines, and immune-modulating gene
therapies.
Panel recommendations
For the diagnosis of mesothelioma, an adequate
tissue biopsy should be used. The pathology report
for mesothelioma should preferably include the histologic subtype, specifically epithelioid, biphasic, or
sarcomatoid.
► Germline genetic testing for BAP1 mutation should be
considered for patients with mesothelioma especially
those with a family history of mesothelioma or other
BAP1 associated cancers such as uveal melanoma,
cutaneous melanoma, kidney or bladder cancer, or
age less than 60 years (LE:4).
► In newly diagnosed patients with mesothelioma, a
multidisciplinary approach that includes consultation with thoracic surgeons, pulmonologists, radiation oncologists, and medical oncologists should be
considered to determine if they are candidates for
maximum cytoreductive operation such pleurectomy
and decortication or extrapleural pneumonectomy
with or without radiation therapy.
► Whenever possible, patients should be offered participation in clinical trials.
► For patients with epithelioid subtype mesothelioma,
treatment with nivolumab plus ipilimumab may be
considered based on comparable outcomes to SOC
chemotherapy. However, treatment decisions should
be individualized and take into account the differing
side effect profiles of combination immunotherapy
and chemotherapy (LE:2).
► For patients with non-
epithelioid subtype mesothelioma, treatment with nivolumab plus ipilimumab is
strongly recommended based on an almost twofold
increase in median OS compared with SOC chemotherapy (LE:2).
► For patients with mesothelioma, routine PD-L1 testing
is not recommended, as benefit from immunotherapy
with nivolumab plus ipilimumab was seen regardless
of PD-L1 expression (LE:2).
► Routine TMB testing is not recommended for patients
with mesothelioma.
► For patients with mesothelioma that has progressed
following front-
line treatment with nivolumab and
ipilimumab, platinum-
based chemotherapy with
pemetrexed should be considered (LE:2).
► Patients with mesothelioma that have progressed
following immunotherapy and pemetrexed with
platinum-based chemotherapy should be encouraged
to enroll in clinical trials.
►

RADIOGRAPHIC RESPONSE TO IMMUNOTHERAPY
RECIST was developed for radiographic evaluation of
response to cytotoxic therapy,113 with an updated version,
RECIST v1.1, developed in 2009.114 115 RECIST defines
progressive disease as the appearance of new lesions
or an increase in the sum of target lesion diameters
16

of ≥20%. However, the assumption that increases in
lesion size or number reflect disease progression (and
therefore treatment failure) does not always hold true for
patients treated with ICIs. In patients treated with ICIs,
a phenomenon known as pseudoprogression has occasionally been observed, in which a lesion appears to grow
at the first imaging check, but then stabilizes and begins
to shrink.116 The incidence of pseudoprogression is low:
of 2,400 patients across multiple cancer types, 6% exhibited atypical response. In the same systematic review, the
pooled rate of atypical responses for patients with NSCLC
was 5% (from a total of 794 patients evaluated).117 The
temporary expansion described as pseudoprogression is
hypothesized to be associated with a delay in treatment
action as the immune response develops, or may be due
to inflammation caused by immune cell infiltration.118–120
Although pseudoprogression is uncommon, conventional RECIST inadequately predicts outcomes in patients
treated with ICIs, motivating the development of alternative response criteria. These alternative response criteria
include the immune-related response criteria (irRC),121
immune RECIST (iRECIST),122 immune-modified
RECIST (imRECIST),123 and immune-
related RECIST
(irRECIST),124 as well as a revised modified response
criteria specific for mesothelioma.125 All of these alternative criteria incorporate different methods to assess
and assign progressive disease versus pseudoprogression. RECIST and its derivatives recommend scheduling
assessments on a regular calendar, ideally coinciding with
treatment cycles (eg, intervals of 6–8 weeks while on treatment). Although formal response criteria can be cumbersome to apply in the SOC setting, response evaluation
should be performed regularly to inform whether consideration should be given to switching therapy.
For patients with lung cancer specifically, a single-
institution analysis of 166 patients with NSCLC receiving
anti-
PD-
1 therapy compared RECIST v1.1, irRC, and
iRECIST for response evaluation. Fifteen (9%) of these
patients were clinically suspected of pseudoprogression,
and follow-up determined that three patients (2% of the
total) experienced genuine pseudoprogression. In all
three cases, the RECIST v1.1 criteria would assign these
patients a status of progressive disease, but both irRC
and iRECIST would flag these patients for additional
follow-up to distinguish between pseudoprogression and
true progression.126 For this reason, treatment beyond
progression for a limited time period is reasonable.
However, if disease progression continues to be observed
in subsequent follow-up, a delayed response should not
necessarily be expected.
Similarly to pseudoprogression, an event known as nodal
immune flare (NIF) was occasionally observed in patients
participating in the phase II, open-label NEOSTAR trial
(NCT03158129), in which neoadjuvant nivolumab with
or without ipilimumab was compared with historical
controls of neoadjuvant chemotherapy for patients with
NSCLC. NIF is a clinically observed phenomenon of an
apparent radiographic lymph node (mediastinal and
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systemic) disease progression, but without pathological
evidence of cancer within the lymph node. Rather, these
lymph nodes exhibit the evidence of de novo sarcoid-
type non-caseating granulomata on pathologic evaluation
following the administration of ICI therapy. NIF occurred
in 5 of 44 patients (11%) in the NEOSTAR trial.127
Another atypical pattern of response occasionally
observed with ICI treatment is hyperprogression, where
a profound increase in tumor growth rate is seen after
therapy. While hyperprogression is also uncommon, it is
a serious event that is associated with significantly shorter
median OS. In an analysis of 406 patients with NSCLC
that received ICI treatment, 13.8% of patients experienced hyperprogression, and patients who developed
hyperprogression within the first 6 weeks of ICI treatment had median OS of 3.4 months (95% CI 2.8 to 7.5),
compared with a median OS of 6.2 months (95% CI 5.3 to
7.9) in patients with typical progressive disease (HR 2.18;
95% CI 1.29 to 3.69; p=0.003).128
As new indications emerge for immunotherapy, further
challenges in radiographic assessment are likely to arise.
For example, clinical trials are currently exploring the
role of neoadjuvant chemo-immunotherapy for the treatment of lung cancer. In the NEOSTAR trial, pathologic
response was positively correlated with radiographic
response.127 However, results from the phase II, open-
label NA_00092076 trial (NCT02259621) did not show
a correlation between radiographic and pathologic
response following neoadjuvant nivolumab,129 indicating that neoadjuvant ICI treatment may carry unique
concerns for radiographic imaging.
Panel recommendations
For patients commencing ICI-based therapy for lung
cancer, a baseline CT should be performed within 4
weeks before the first dose of therapy.
► The first follow-up CT imaging on therapy should be
performed 6–9 weeks (approximately 2–3 treatment
cycles) after the commencement of ICI-based therapy,
and the timing should be adapted to the dosing
schedule of the systemic therapy.
► If a patient is clinically stable or improved, it is reasonable to continue therapy beyond radiographic progression. Repeat CT imaging should be performed within
4–8 weeks to rule out continued disease progression
and monitor for toxicities.
► For a patient who has been treated with immunotherapy beyond radiographic progression and has
continued disease progression at the time of follow-up
imaging and/or clinical deterioration, strong consideration should be given to looking for an alternative
systemic therapy.
►

UNDERSTUDIED PATIENT POPULATIONS
Because of concerns about the potential for increased
toxicity and compromised efficacy, patients with pre-
existing autoimmunity have been largely excluded from
prospective randomized trials of ICI therapy for cancer.

Available information comes mostly from retrospective
case series, which may carry selection and confounding
biases toward relatively lower risk autoimmune disorders.
Some case series have attempted to differentiate between
a flare of the patient’s underlying autoimmune disorder
versus a de novo immune-related adverse event (irAE).130
However, the patients in these case series had a wide
variety of autoimmune disorders, complicating the risk
calculation for flares with ICI therapy associated with any
specific disorder.
Small studies have indicated that flares on ICI treatment are generally manageable and ORRs in patients with
pre-existing autoimmunity are comparable to the general
population. A retrospective multi-
institutional analysis
of 56 patients with NSCLC and an existing autoimmune
disease including rheumatoid arthritis, polymyalgia rheumatica, thyroiditis, ulcerative colitis/Crohn’s disease,
and psoriasis found that during ICI treatment, 23% of
patients experienced flares of their existing autoimmune
conditions, and irAEs occurred in 38% of patients. Only
5% of these patients developed both an irAE and a flare
of their autoimmune disease. The majority (87%) of
autoimmune flares were grade 1 or 2, and the flares were
generally manageable; no patients that experienced a
flare permanently discontinued anti-PD-(L)1 treatment.
The ORR for the previously treated patients in this study
was 22%, and no association was found between flares
and response to ICIs.131 A phase I, open-label clinical
trial (NCT03816345) is ongoing at the time of guideline preparation to study the use of nivolumab to treat a
variety of advanced, metastatic, and unresectable cancers
in patients with existing autoimmune disorders.
Similarly, patients who have received solid organ
transplants (SOTs) have largely been excluded from ICI
clinical trials due to concerns that ICI-induced immune
activation could result in transplant rejection, and
therefore the safety of treating these patients with ICIs is
largely unknown. A limited number of reports including
patients with SOTs and metastatic cancers treated with
ICI therapies suggest that rejection is not universal, but
is sufficiently frequent to warrant concern.132–134 In a
systematic review of 39 patients treated for a variety of
tumor types with ICIs that had received SOTs, 16 (41%)
experienced allograft rejection, which progressed
to graft loss in 13 patients. The immunosuppressive
regimen patients were receiving at the time of ICI
therapy initiation may have influenced the likelihood of
allograft rejection; patients who received single-agent
prednisone appeared to be more likely to experience
graft rejection than those who received single-
agent
calcineurin inhibitors. The mortality rate for patients
with SOTs that received ICIs was high, since 18 patients
(46%) died, most commonly due to allograft rejection
or associated complications.133
Irrespective of risk of transplant rejection, however,
objective responses after ICI treatment have been
reported, and may vary by tumor type in the presence
of allograft immunosuppression.132–134 Thus, in the

Govindan R, et al. J Immunother Cancer 2022;10:e003956. doi:10.1136/jitc-2021-003956

17

J Immunother Cancer: first published as 10.1136/jitc-2021-003956 on 31 May 2022. Downloaded from http://jitc.bmj.com/ on June 7, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

case of metastatic NSCLC for which no other treatment
options exist, it may be appropriate in some cases to
weigh the risks of rejection against the potential benefit
of inducing an antitumor response and prolonging
survival. For example, a patient who has undergone a
kidney transplant may consider treatment with an ICI as,
in the event of acute rejection, dialysis is an option. By
contrast, a patient who has undergone a liver or cardiac
transplant risks fatality should acute rejection occur.
A phase I, open-label clinical trial (NCT03816332) is
enrolling patients with renal transplants and unresectable or metastatic cancers to examine the use of
tacrolimus, nivolumab, and ipilimumab as a treatment
regimen for these patients.
Patients receiving baseline treatment with corticosteroids may experience worse outcomes during ICI
treatment for NSCLC, depending on the dose and
reason for immunosuppressive use (eg, palliative vs
cancer-unrelated reasons). A retrospective analysis of
650 patients with NSCLC who received ICI treatment
found that those who had received ≥10 mg of prednisone within 24 hours of beginning treatment with
ICIs (n=93) exhibited a lower ORR of 10.8% (95%
CI 5.9% to 18.6%) compared with 19.7% (95% CI
16.5% to 23.3%) in patients who had received 0 to <10
mg of prednisone (n=557; p=0.04). Patients who had
received ≥10 mg of prednisone also exhibited shortened
median PFS, at 2.0 months versus 3.4 months (HR 1.36;
95% CI 1.08 to 1.73; p=0.01), and shortened median
OS, at 4.9 months versus 11.2 months (HR 1.68; 95%
CI 1.30 to 2.17; p<0.001). However, when the patient
group treated with ≥10 mg prednisone was divided into
patients who received prednisone for palliative, cancer-
related reasons and patients who received prednisone
for indications unrelated to cancer, only those patients
who received prednisone for cancer palliation exhibited
significantly worse ORR, median PFS, and median OS.
Further, patients who received prednisone for cancer
palliation were more likely to have a lower ECOG PS.
These results indicate that patients who receive ≥10
mg prednisone for non-cancer indications experience
similar outcomes to those who receive 0–10 mg prednisone, and in turn suggest that corticosteroids may
not impair response to immunotherapy in patients with
good performance status.135
Patients with ECOG PS 2 are also under-represented in
clinical trials. Some studies, such as CheckMate 812, have
found a consistent safety profile for dual immunotherapy
in special populations with metastatic NSCLC, including
participants with asymptomatic untreated brain metastases, hepatic or renal impairment, or HIV.136 Additional
trials are needed to validate safety and efficacy in these
populations with high unmet need.
Panel recommendations
► For patients with advanced lung cancers and
active autoimmune conditions or SOTs, the use of
18

►

►

►

immunotherapy merits a thoughtful multidisciplinary
approach requiring a discussion with the treating
team, including subspecialists and the oncologist, and
the patient regarding the risk of autoimmune activation against the potential for benefit with ICI treatment. Given the lack of prospective clinical trial data,
whenever possible patients in these groups should be
encouraged to enroll in clinical trials.
Baseline interstitial lung disease and/or a high risk
for pneumonitis are relative contraindications to ICI
therapy (LE:3).
For patients with pre-existing autoimmune disorders
that are controlled with chronic low dose immunosuppression, ICI therapy is not necessarily absolutely
contraindicated. However, immunotherapy should
be avoided in patients with poor control of autoimmune disease (requiring high doses of immunosuppressants) and in patients with life-threatening and/
or CNS autoimmune disease (LE:3).
For patients with SOTs, the impact of graft rejection
should be weighed against the potential benefit of ICI
treatment. In most cases, the ramifications of graft
rejection will outweigh the palliative benefits of ICI
treatment, although renal transplant patients may
represent an exception (LE:1).

RECOGNITION AND MANAGEMENT OF IRAES
Immunotherapies are associated with a distinct profile of
toxicities compared with conventional cancer treatments,
which are known as irAEs. A number of guidelines exist on
general principles concerning the diagnosis and management of irAEs, including from SITC,137 138 the National
Comprehensive Cancer Network,139 and the American
Society of Clinical Oncology.140 In addition to a CPG138
SITC has also published a guidebook141 to assist in the
management of toxicity. Patients with lung cancer may
be at increased risk for developing specific lung-related
irAEs, which is why the recognition and management
of these toxicities is critical before proceeding with an
immunotherapy treatment plan. As described in SITC’s
guideline, ruling out other potential causes of pneumonitis is vitally important to safely manage irAEs in ICI-
treated patients.
While most irAEs occur during or shortly after the
period of treatment, they may also occur months after
treatment has concluded.142 Two analyses of ICI-treated
patients who developed pneumonitis found similar
median times to onset, at 2.8 months (multiple tumor
types)143 and 82 days (patients with NSCLC).144
A particular concern when administering ICIs to
patients with lung cancer is an increased incidence of
pneumonitis, a potentially serious irAE that is associated with lower survival in patients who receive immunotherapy for lung cancer.145 146 A meta-analysis of clinical
trials of anti-PD-1 ICIs found that patients with NSCLC
developed pneumonitis at a higher rate than patients
with melanoma, both for all-grade pneumonitis (4.1%
vs 1.6%; p=0.002) and for grade ≥3 pneumonitis (1.8%
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vs 0.2%; p<0.001). This analysis also found that combination therapies that included ICIs also carried a significantly higher risk of pneumonitis compared with ICI
monotherapy, with higher odds for all-grade (OR 2.04;
95% CI 1.69 to 2.50; p<0.001) and grade ≥3 (OR 2.86;
95% CI 1.79 to 4.35; p<0.001) pneumonitis.147 Additional
risk factors for ICI-induced pneumonitis include prior
radiotherapy (curative-
intent, chest)86 and squamous
histology (as compared with adenocarcinoma histology)
for patients with NSCLC,144 and pneumonitis that does
not respond to corticosteroid treatment may be more
common in patients with a history of other lung conditions or smoking.143
Another potentially serious irAE of particular concern
for patients with NSCLC is ICI-associated interstitial lung
disease (ILD). An analysis of 83 patients with NSCLC
treated with ICIs found that the presence of pre-existing
interstitial lung abnormalities (specifically ground-glass
attenuation) was associated with significantly higher
(p<0.001) incidence of ICI-associated ILD.148
Panel recommendations
For patients with lung cancer receiving ICI therapy
who develop symptoms of irAEs, management should
follow established guidelines. The management of
ICI-
related toxicity in patients with lung cancer is
identical to management in other malignancies.

►

PATIENT SUPPORT AND QOL
A vital component of any cancer treatment plan is patient
education, with the potential to reduce anxiety and
enhance patients’ ability to manage fatigue.149 Patient
education can be given in a variety of formats, and ideally
can be tailored to accommodate patients with different
styles of learning or with barriers that may inhibit understanding.150 For patients being treated with immunotherapies, specifically, it is important to emphasize that
the mechanism of action responsible for the anticancer
activity of the therapies they receive and that, therefore,
the AEs associated with immunotherapy agents are both
drastically different from conventional chemotherapies
and radiotherapy. It is also important to provide patients
with information on the symptoms and expected timing of
irAEs.151 Beyond verbal instruction, tools to assist patients
and caregivers in the monitoring of potentially serious
irAEs include symptom checklists, wallet cards, and telephone triage guidelines specific to immunotherapy could
assist healthcare professionals in effectively assessing and
managing irAEs.
It is also important to consider the patient’s QOL
during and after completion of therapy. A survey of
660 patients with lung cancer found that patients rated
QOL, maintaining independence, ability to perform
normal activities, ability to sleep, and fatigue as their most
important concerns.152 Assessments of health-
related
QOL (HRQOL) have found that both the symptoms of
lung cancer (commonly including fatigue, loss of appetite, dyspnea, cough, and pain)153 and treatments for lung

cancer can have significant impacts on HRQOL. These
can contribute to higher levels of distress, anxiety, and
depression in patients with lung cancer compared with
other cancers.154 155 While treatment for lung cancer
typically enhances HRQOL, this is dependent on both
the patient’s symptom burden and on the treatment
regimen.156–158 However, HRQOL indicators (mental,
physical, social, spiritual, and emotional) often remain
unrecognized and under-
reported, which can lead to
increased symptom burden, decreased adherence to treatment, lower satisfaction with care, and worse outcomes
including decreased survival.159–163
Financial toxicity is an increasingly important factor
affecting patient QOL, especially considering that immunotherapies may be among the most expensive drugs
on the market. A prospective study of 1,000 patients
with lung or colorectal cancer found that 48% reported
difficulty living on their household income, and financial distress was associated with poorer QOL.164 Patients
with worse financial burden exhibit worse psychological
outcomes, and an assessment of 654 patients with a variety
of solid tumor types found that the risk of depression
was three times higher in patients reporting increased
cancer-related financial stress (OR 2.79; 95% CI 1.87 to
4.17) or cancer-related financial strain (OR 3.56; 95% CI
2.23 to 5.67). Patients under increased financial burden
were similarly at increased risk of anxiety and distress.165
Finally, financial toxicity may result in patients being
unable to fully adhere to treatment plans, by taking less
than the prescribed amount of medication, partially
filling prescriptions, or not filling prescriptions at all.166
Even for patients with health insurance coverage, the
high cost of medications may result in financial toxicity
due to incomplete coverage and additional costs beyond
the price of the drugs themselves, such as, for example,
out-of-pocket expenses associated with frequent hospital
visits or unexpected inpatient stays due to AEs.
A number of tools have been developed to assess
HRQOL, including several that rely on patient-reported
outcomes (PROs). PROs may be general assessments of
QOL or HRQOL, as in the European Quality of Life Five
Dimensions,167 European Organization for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30),168 and the Functional Assessment of Cancer Therapy (FACT)169 or they
may be specific to a disease state, as in the Lung Cancer
Symptom Scale,170 the EORTC Quality of life Questionnaire Lung Cancer 13 items (QLQ-
LC13),168 and the
171 172
FACT-Lung.
Tools have also been developed to more
specifically assess PROs in patients receiving immunotherapy, including the Functional Assessment of Chronic
Illness Therapy Immunotherapy item library173 and the
FACT-Immune Checkpoint Modulator.174
A number of clinical trials involving ICIs have shown
the HRQOL effects for immunotherapies compare favorably to other modalities. For example, the KEYNOTE-024
trial, which used the QLQ-C30 and QLQ-LC13 to assess
changes in QOL and time to deterioration of symptoms,
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reported that patients receiving pembrolizumab exhibited significantly improved changes in QOL scores
compared with patients receiving chemotherapy, with
a scoring difference between the two treatment groups
of 7.8 (95% CI 2.9 to 12.8; p=0.002) from baseline to
15 weeks of treatment. Patients who received pembrolizumab also had higher median time to deterioration,
with the median not reached (95% CI 8.5 months to not
reached) for pembrolizumab compared with 5.0 months
(95% CI 3.6 to not reached) for chemotherapy (HR 0.66;
95% CI 0.44 to 0.97; p=0.029).175 PRO results from the
OAK study comparing atezolizumab to docetaxel showed
similarly positive results for atezolizumab treatment.
Patients treated with atezolizumab exhibited significantly
longer time to deterioration in physical function, with
the median not estimable (95% CI 13.2 months to not
estimable) for atezolizumab and 6.7 months (95% CI 5.1
to not estimable) for docetaxel (HR 0.75; 95% CI 0.58
to 0.98; p=0.0329). However, differences in HRQOL were
not significant between the two arms of this study.176
Panel recommendations
All patients receiving treatment with ICIs should
receive detailed education about the potential
immune-related toxicities associated with therapy.
► Support tools should be provided to guide patients
and caregivers in self-monitoring to support appropriate intervention.
► It is important to discuss the financial impact of
immunotherapy treatment with patients and their
care-partners, and to assist in identifying resources for
them to find support.
►

CONCLUSION
Lung cancer has been and continues to be one of the
foremost disease settings in which the incoporation of
immunotherapy agents into the SOC has lead to durable
responses and significant improvements in survival in
many treatment settings, and the field continues to
rapidly evolve. Still, lung cancer exerts a substantial
health burden in the US and around the world, and is
a major cause of cancer-related mortality. This guideline
provides an update to SITC’s previous NSCLC CPG,177
with additional guidance on new indications for immunotherapy agents in NSCLC, as well as the SCLC and mesothelioma disease settings. While checkpoint blockade has
become a cornerstone for the treatment of late-stage or
R/R disease, the efficacy of immunotherapy in earlier
stages of disease is an ongoing area of investigation that
may potentially expand the population of patients who
benefit. Additionally, combination regimens including
one or more immune-targeting agents with synergistic
activity to ‘conventional’ modalities such as chemotherapy, radiotherapy, or targeted therapies may further
increase response rates and expand the landscape of
treatment options. Future prospective trials to identify
and validate biomarkers of response to immunotherapy
will also be key to providing optimal care to patients
20

with lung cancer and mesothelioma. Exciting areas for
future research include the use of circulating-tumor DNA
for response assessment in the metastatic setting as well
as measurement of minimal residual disease to guide
adjuvant treatment for resectable tumors. With several
ongoing, large-scale clinical trials in progress at the time of
guideline preparation, the existing indications for immunotherapy in lung cancer will likely continue to expand.
These guidelines will be updated as the field continues
to develop and updates will be available on SITC’s CPG
application (www.sitcancer.org/cpg-app).
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